Inhibitors of IL-17A and its receptor have emerged as important targets for the treatment of autoimmune diseases (such as rheumatoid arthritis, psoriasis, etc.)and inflammatory bowel diseases (26). The gene discussed is IL17A; the disease is inflammatory bowel disease.